Get started
PFIZER INC. DL-,05PFIZER INC. DL-,05PFIZER INC. DL-,05

PFIZER INC. DL-,05

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

peeking $PFE's levels to manage my positionPfizer Inc. is the best gene therapy stock to buy now. Pfizer expects an FDA decision for Marstacimab, a potential once-weekly subcutaneous treatment for hemophilia B. They also started a Phase 3 study for osivelotor in sickle cell disease. New Product Approvals: Pfizer’s recent product approvals include Abrysvo RSV vaccine, Velsipity (etrasimod) for ulcerative colitis, Penbraya pentavalent meningococcal vaccine, Zavzpret nasal spray for migraine, Litfulo (ritlecitinib) for severe alopecia areata, and Beqvez (fidanacogene elaparvovec), a one-time gene therapy for hemophilia B.
NYSE:PFELong
by KhanhC.Hoang
Pfizer !!! low risk , 20% Gain till next month ?? Hello everyone, today I want to discuss Pfizer's stock which experienced a 58% correction from its peak price and is currently trading around $26. I believe this stock has a lot of potential for both scalpers and long-term investors. With a dividend yield of 6.65% at this price, it's an attractive investment option. Additionally, the earnings report due this week could boost the stock price to $30 by next month. You can refer to the chart for trade stop and stop-loss points. Disclaimer: This information or service is for informational purposes only and is not intended to be personal financial advice #pfizer
NYSE:PFELong
by S_INV28
1
Trade Like A Sniper - Episode 16 - Pfizer - (5th June 2024)This video is part of a video series where I backtest a specific asset using the TradingView Replay function, and perform a top-down analysis using ICT's Concepts in order to frame ONE high-probability setup. I choose a random point of time to replay, and begin to work my way down the timeframes. Trading like a sniper is not about entries with no drawdown. It is about careful planning, discipline, and taking your shot at the right time in the best of conditions. A couple of things to note: - I cannot see news events. - I cannot change timeframes without affecting my bias due to higher-timeframe candles revealing its entire range. - I cannot go to a very low timeframe due to the limit in amount of replayed candlesticks In this session I will be analyzing PFE (Pfizer), starting from the 4-Month chart. - R2F
NYSE:PFE
by Road_2_Funded
Analysis of PFE Price: Is the Stock Undervalued?Analysis of PFE Price: Is the Stock Undervalued? Yesterday, the price of Pfizer's stock rose by more than 2.2%, while the S&P 500 index remained almost unchanged from the opening to the closing of trading. This fact is noteworthy, considering that for many months the price of PFE stock performed worse than the market - if the S&P 500 grew by 23% during 2023, then the price of PFE decreased by approximately 43%. The decline in 2023 (shown by the red channel) was disappointing. But what about now - is the situation changing? Are investors missing out on something important by turning away from PFE? Several factors indicate that PFE stock may have optimistic prospects. Fundamentally - Investors Place has included PFE in the list of the most undervalued stocks for reasons such as: → 2023 saw a record number of FDA approvals. New drugs could boost sales. → Pfizer acquired Seagen, significantly expanding its capabilities in cancer research. This supports the company's strategy to become a world-class leader in oncology. → By 2030, Pfizer plans to release 8 drugs that could become "blockbusters." From a technical analysis perspective of the daily chart of PFE: → Attention is drawn to the 3 candles from December 13-15, 2023 - on each of these days, over 100 million shares were traded on the NYSE, which is unusually high for this market. Large investors may have been building long positions - as the price of PFE rose out of the zone marked by the 3 candles in purple. → Throughout 2024, the price attempted to drop below the indicated zone, but each time it did not make progress. → The decline on April 25 looks like a Final Shakeout pattern in Richard Wyckoff's terminology, indicating the completion of the stock accumulation process. The price action in May 2024 looks extremely bullish: → PFE stock is outperforming the market. → The RSI indicator remains above the level of 50. → The downtrend has been broken. According to TipRanks, the average forecasted price of PFE stock by Wall Street analysts is $33.15 (+13.10% from current levels). Buy and sell stocks of the world's biggest publicly-listed companies with CFDs on FXOpen’s trading platform. Open your FXOpen account now or learn more about trading share CFDs with FXOpen. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:PFE
by FXOpen
2
Pfizer implements $1.5bn cost-cutting initiative. Idea 27/05/24Pfizer Inc. (PFE) has announced a new multi-year plan to reduce operational costs by approximately 1.5 billion USD by the end of 2027. This initiative is in addition to a previously announced 4 billion USD cost reduction strategy in response to decreased investments and a sharp decline in sales from its COVID-19 vaccine. Amid these challenges, Pfizer has actively restructured its operations, including acquiring cancer drug manufacturer Seagen for 43 billion USD, aiming to diversify and strengthen its product portfolio. Despite these financial adjustments, Pfizer has raised its full-year earnings forecast following better-than-expected earnings in Q1. These results were partly attributed to the successful implementation of cost-saving measures. To bolster its financial standing, the company focuses on operational efficiency, restructuring its network, and enhancing its product portfolio. Given this backdrop, let's examine the potential trading opportunities for Pfizer Inc. (NYSE: PFE): On the Daily (D1) timeframe, Pfizer's stock shows a resistance level at 29.65 USD and support at 28.45 USD. The resistance line of the ongoing downtrend has been breached, suggesting a potential shift in market sentiment. If the trend reverses downward, a possible target might be 25.30 USD. If the current uptrend persists, a short-term target is 31.90 USD upon rebounding from the 29.65 USD resistance level. For a medium-term strategy, the stock price could reach 34.10 USD if the upward momentum continues. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:PFE
by RoboMarkets
Is this the beginning of a reversal? Pfizer (PFE) experienced a significant surge when they became the first to develop a vaccine against the virus whose name should not be spoken. Afterward, investors took profits, leading to a decline in the stock's chart. Currently, the price has reached the lower band of the parallel channel, suggesting that sellers might switch to buyers. Regarding the indicators: - The 3 Line Indicator shows a reversal, with all three lines forming a triple bottom. The red line (short trend) is already moving higher. - The RSI is breaking out of a channel and pointing straight to the upside, with a bullish divergence in the lower timeframes. - A rare green bullish signal has appeared on the chart, indicating a pivotal moment. This could be the bottom of a long downtrend for Pfizer. I look forward to seeing more developments. #Pfizer
NYSE:PFELong
by ValerianK
PFE | Time to Accumulate | LONGPfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
NYSE:PFELong
by DivergenceSeeker
Bad idea to go long on PFE?Here I am again with another trade. Pfizer is one of the many stocks I have been following for quite a time waiting for a good setup and I think now it's the time to go long, Bullish RSI divergence, probable double bottom on a long time strong support area. We know this company has received a lot of heat because of covid, but Pfizer is a strong player in the healthcare industry so I hope it will rise again after all this tech AI mania goes over. I'm buying PFE for a swing trade, let's see how it goes in a few months.
NYSE:PFELong
by devdalistudio
2
Pfizer Wins $107.5 Million From AstraZeneca in US Cancer DrugPfizer ( NYSE:PFE ) has won $107.5 million in damages from AstraZeneca in a US cancer drug patent trial. A Delaware federal jury found that AstraZeneca's lung cancer drug Tagrisso violated its Wyeth unit's patent rights. The jury agreed that AstraZeneca's drug infringed two patents covering methods for treating cancer with the breast-cancer drug Nerlynx, which is sold by Puma Biotechnology. Puma licenses the patents from Pfizer ( NYSE:PFE ) to make its drug. AstraZeneca, which earned AstraZeneca nearly $5.8 billion in revenue last year, denied infringing the patents and argued they are invalid. Pfizer ( NYSE:PFE ) is no longer a plaintiff in the case. A separate bench trial on some of AstraZeneca's remaining defenses is set to be held in June, which could result in a ruling that negates the verdict. Technical Outlook Pfizer ( NYSE:PFE ) closed Friday's trading at $28.64 down by 0.97%. The stock has a Relative Strength Index (RSI) of 64.11 which is liable for further growth. Pfizer ( NYSE:PFE ) stock is set to rise from its Falling Wedge Pattern which started from the 6th of January, 2024.
NYSE:PFE
by DEXWireNews